首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   156895篇
  免费   31692篇
  国内免费   2805篇
耳鼻咽喉   5193篇
儿科学   5418篇
妇产科学   2464篇
基础医学   3691篇
口腔科学   1619篇
临床医学   27301篇
内科学   48069篇
皮肤病学   7543篇
神经病学   14981篇
特种医学   6600篇
外国民族医学   1篇
外科学   41902篇
综合类   1376篇
现状与发展   73篇
预防医学   7579篇
眼科学   3531篇
药学   1506篇
  5篇
中国医学   362篇
肿瘤学   12178篇
  2024年   699篇
  2023年   4868篇
  2022年   1348篇
  2021年   3348篇
  2020年   6185篇
  2019年   2358篇
  2018年   7571篇
  2017年   7478篇
  2016年   8565篇
  2015年   8621篇
  2014年   15754篇
  2013年   15845篇
  2012年   5771篇
  2011年   5801篇
  2010年   10575篇
  2009年   14415篇
  2008年   6006篇
  2007年   4316篇
  2006年   6736篇
  2005年   3954篇
  2004年   3355篇
  2003年   2432篇
  2002年   2473篇
  2001年   4160篇
  2000年   3249篇
  1999年   3376篇
  1998年   3717篇
  1997年   3537篇
  1996年   3417篇
  1995年   3256篇
  1994年   1967篇
  1993年   1588篇
  1992年   1439篇
  1991年   1473篇
  1990年   1108篇
  1989年   1238篇
  1988年   1063篇
  1987年   903篇
  1986年   932篇
  1985年   762篇
  1984年   586篇
  1983年   534篇
  1982年   519篇
  1981年   401篇
  1980年   360篇
  1979年   321篇
  1978年   338篇
  1977年   409篇
  1975年   282篇
  1972年   306篇
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
31.
32.
33.
This review discusses treatment options for men with premature ejaculation (PE), a common sexual dysfunction characterized by short ejaculatory latency, decreased sexual satisfaction, and distress. For a number of reasons, including embarrassment and the belief that PE is a normal part of aging, that it has no effective treatment, or that it will resolve itself, few men with PE seek treatment. Although several treatment options exist (eg, behavioral, cognitive, and sex therapy methods; desensitizing drugs; off-label use of antidepressants, phosphodiesterase type 5 inhibitors, or à-blockers), the majority of men with PE are not satisfied with their results. New pharmacologic drugs develped specifically for the treatment of PE are undergoing evaluation in clinical trials. For example, recent clinical research studies have revealed on-demand administration of one such drug, dapoxetine, which achieved significant improvements in ejaculatory latency, control over ejaculation, and satisfaction with sexual intercourse. In addition, partners of men who received dapoxetine likewise reported improved satisfaction with sexual intercourse. Future studies may reveal that integration of pharmacologic drugs with psychologic and/or behavioral therapy techniques may be the optimal approach to the management of PE. PE is a treatable condition, and new drugs in development may provide benefits over those available.  相似文献   
34.
35.
36.
Editorial     
  相似文献   
37.
38.
Prostatitis and male infertility are frequent disorders, and the role of prostatitis in male infertility has been under discussion for more than 30 years. Many researchers have shown relevant links between the two. Although a causal relationship has not been definitely demonstrated, increasing evidence shows that chronic prostatitis has a relevant negative impact on male fertility potential, at least in certain subgroups. In the following review, we focus on the present state of knowledge on the role of chronic prostatitis as an etiologic factor in male infertility.  相似文献   
39.
Medical therapy is currently the most popular treatment choice for lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Because medical therapy of BPH-related LUTS is considered a life-long strategy, short- and long-term cost considerations should play a major role in therapeutic decision-making. The effectiveness in terms of long and short amelioration of symptoms, flow rate, and quality of life are well documented for 5α-blockers and 5α-reductase inhibitors as well as for the gold standard treatment for BPH, transurethral resection of the prostate and minimally invasive therapies. Short-and long-term safety concerns also are well documented for these various treatment options. On the contrary, short- and long-term costs have been less well studied and comparisons depend on the model or analyses undertaken in the few studies available. However, the economic studies based on prospective clinical trial data that have become available throughout the past several decades allow us to rationalize our use of α-blockers, 5α -reductase inhibitors, and combination therapy, taking into consideration age, severity of symptoms, prostate volume, prostate-specific antigen, and the differential response of the various medications (and combination) in selected patients. Based on current studies, 5α -blockers generally provide cost-effective therapy for most patients, whereas 5α-reductase therapy and combination therapy provide cost-effective treatment for patients with larger prostate glands or higher baseline prostate-specific antigen levels.  相似文献   
40.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号